{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:04:18Z","timestamp":1790701458267,"version":"4.1.0"},"reference-count":32,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Council of Thailand (NRCT), NRCT-Research Career Development Grant","award":["NRCT5-RSA63011-04"],"award-info":[{"award-number":["NRCT5-RSA63011-04"]}],"id":[{"id":"https:\/\/ror.org\/018wfhg78","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NRCT, the Royal Golden Jubilee (RGJ) Ph.D. Programme","award":["N41A680262"],"award-info":[{"award-number":["N41A680262"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Cholangiocarcinoma (CCA) is an aggressive bile duct malignancy with a high incidence and mortality rate in Southeast Asia, particularly in Thailand. However, current treatments offer only limited clinical benefit. Aberrant mRNA splicing, driven by hyperactivation of serine\/arginine-rich splicing factors (SRSFs) and their upstream kinases SRPK1 and SRPK2, contributes to the progression of CCA. Although SRPK inhibitors suppress tumor growth, their effects remain incomplete, highlighting the need for rational combination strategies. Methods: Liquid chromatography\u2013tandem mass spectrometry (LC-MS\/MS)-based proteomic profiling was performed on CCA cell lines (KKU-213A and KKU-055) treated with the SRPK inhibitors SRPIN340 and SPHINX31. Subsequently, commonly upregulated differentially expressed proteins (UpDEPs) were identified and cross-validated with data from the Cancer Genome Atlas (TCGA) using GEPIA, followed by reverse transcription-quantitative polymerase chain reaction (qRT-qPCR) validation. The functional effects of combined SRPK and mitogen-activated protein kinase kinase (MEK) inhibition (with U0126) were evaluated using cell viability and colony formation assays, and by analyzing signaling pathways. Results: A total of 34 common UpDEPs were identified following SRPK inhibition. Laminin subunit beta 1 (LAMB1) was prioritized as a candidate combination target due to robust upregulation, concordant overexpression in TCGA datasets, and increased mRNA levels after SRPK inhibitor treatment. Given prior evidence linking MEK signaling to LAMB1 regulation, we also evaluated the MEK inhibitor U0126. Combined treatment with SRPK inhibitors (SRPIN340 or SPHINX31) and U0126 produced greater suppression of viability and clonogenic growth in KKU-213A cells than either treatment alone. These effects were accompanied by reduced ERK phosphorylation and cellular Jun proto-oncogene (c-JUN) expression. Conclusions: LAMB1 represents a potential adaptive response target following SRPK inhibition in CCA. Dual targeting of SRPK and MEK signaling pathways exerts greater antitumor effects than either treatment alone and may provide a promising therapeutic strategy for CCA management.<\/jats:p>","DOI":"10.31083\/fbl52847","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:51Z","timestamp":1790698911000},"source":"Crossref","is-referenced-by-count":0,"title":["SRPK Inhibition in Cholangiocarcinoma Cells Induces LAMB1-Associated Adaptive Responses and Enhances Growth Suppression by the MEK Inhibitor U0126 via the LAMB1\/ERK\/c-JUN Axis"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2141-9165","authenticated-orcid":true,"given":"Chaturong","family":"Inpad","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakasit","family":"Khamsuwan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuwapat","family":"Vongkaewpothong","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waritsara","family":"Susena","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanyanut","family":"Kotanart","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-5575","authenticated-orcid":true,"given":"Tavan","family":"Janvilisri","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Science, Chulalongkorn University, 10330 Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-1692","authenticated-orcid":true,"given":"Hathaichanok","family":"Impheng","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-3843","authenticated-orcid":true,"given":"Atit","family":"Silsirivanit","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Khon Kaen University, 40002 Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-8390","authenticated-orcid":true,"given":"Sittiruk","family":"Roytrakul","sequence":"additional","affiliation":[{"name":"National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, 12120 Pathum Thani, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-5827","authenticated-orcid":true,"given":"Worasak","family":"Kaewkong","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medical Science, Naresuan University, 65000 Phitsanulok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine. 2021; 10: 2368.","DOI":"10.3390\/jcm10112368"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews. Gastroenterology & Hepatology. 2020; 17: 557\u2013588.","DOI":"10.1038\/s41575-020-0310-z"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Banales JM, Rodrigues PM, Aff\u00f2 S, Andersen JB, Aspichueta P, Boulter L, et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nature Reviews. Gastroenterology & Hepatology. 2026; 23: 65\u201396.","DOI":"10.1038\/s41575-025-01153-w"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"da Silva MR, Moreira GA, Silva RA, Barbosa E, Pais SR, Teixeira RR, et al. Splicing regulators and their roles in cancer biology and therapy. BioMed Research International. 2015; 2015: 1\u201312.","DOI":"10.1155\/2015\/150514"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhou X, Li X, Yu L, Wang R, Hua D, Shi C, et al. The RNA-binding protein SRSF1 is a key cell cycle regulator via stabilizing NEAT1 in glioma. The International Journal of Biochemistry & Cell Biology. 2019; 113: 75\u201386.","DOI":"10.1016\/j.biocel.2019.06.003"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Marin JJG, Reviejo M, Soto M, Lozano E, Asensio M, Ortiz-Rivero S, et al. Impact of Alternative Splicing Variants on Liver Cancer Biology. Cancers. 2021; 14: 18.","DOI":"10.3390\/cancers14010018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Siqueira RP, Barbosa \u00c9DAA, Pol\u00eato MD, Righetto GL, Seraphim TV, Salgado RL, et al. Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340). PloS One. 2015; 10: e0134882.","DOI":"10.1371\/journal.pone.0134882"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Inpad C, Phetchahwang P, Pothipan P, Tangwiriyarotkul P, Hongsrichan N, Horpaopan S, et al. Silencing serine\/arginine-rich splicing factor 1 to induce apoptosis and autophagy-dependent cell death in cholangiocarcinoma through the correction of oncogenic splicing errors. Anatomy & Cell Biology. 2025; 58: 602\u2013614.","DOI":"10.5115\/acb.25.052"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, et al. Inhibition of serine\/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicology In Vitro. 2022; 82: 105385.","DOI":"10.1016\/j.tiv.2022.105385"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Changphasuk P, Inpad C, Horpaopan S, Khunchai S, Phimsen S, Surangkul D, et al. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting BIN1, MCL-1 and BCL2 Splicing Errors and Enabling Apoptosis of Cholangiocarcinoma Cells. Frontiers in Bioscience (Scholar Edition). 2024; 16: 17.","DOI":"10.31083\/j.fbs1603017"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lee H, Kim WJ, Kang HG, Jang JH, Choi IJ, Chun KH, et al. Upregulation of LAMB1 via ERK\/c-Jun Axis Promotes Gastric Cancer Growth and Motility. International Journal of Molecular Sciences. 2021; 22: 626.","DOI":"10.3390\/ijms22020626"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Sripa B, Seubwai W, Vaeteewoottacharn K, Sawanyawisuth K, Silsirivanit A, Kaewkong W, et al. Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Human Cell. 2020; 33: 695\u2013708.","DOI":"10.1007\/s13577-020-00334-w"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Panawan O, Silsirivanit A, Chang CH, Putthisen S, Boonnate P, Yokota T, et al. Establishment and characterization of a novel cancer stem-like cell of cholangiocarcinoma. Cancer Science. 2023; 114: 3230\u20133246.","DOI":"10.1111\/cas.15812"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Pratummanee K, Kerdkumthong K, Roytrakul S, Tantimetta P, Runsaeng P, Saeheng S, et al. Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells. Molecular Medicine Reports. 2024; 30: 198.","DOI":"10.3892\/mmr.2024.13322"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nature Protocols. 2016; 11: 2301\u20132319.","DOI":"10.1038\/nprot.2016.136"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Howe EA, Sinha R, Schlauch D, Quackenbush J. RNA-Seq analysis in MeV. Bioinformatics (Oxford, England). 2011; 27: 3209\u20133210.","DOI":"10.1093\/bioinformatics\/btr490"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.). 2001; 25: 402\u2013408.","DOI":"10.1006\/meth.2001.1262"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ladomery M. Aberrant alternative splicing is another hallmark of cancer. International Journal of Cell Biology. 2013; 2013: 463786.","DOI":"10.1155\/2013\/463786"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British Journal of Cancer. 2014; 111: 477\u2013485.","DOI":"10.1038\/bjc.2014.342"},{"key":"ref20","unstructured":"Siriwath J, Wiriyakulsit N, Klomkleang P, Inpad C, Roytrakul S, Kaewkong W. SPHINX31 suppresses splicing factor phosphorylation and inhibits melanoma cell growth and aggressiveness. Journal of Current Science and Technology. 2021; 11: 346\u2013354"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Araki S, Dairiki R, Nakayama Y, Murai A, Miyashita R, Iwatani M, et al. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PloS One. 2015; 10: e0116929.","DOI":"10.1371\/journal.pone.0116929"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, et al. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications. 2018; 9: 5378.","DOI":"10.1038\/s41467-018-07620-0"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Okanishi H, Ohgaki R, Okuda S, Endou H, Kanai Y. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Cancer Science. 2021; 112: 871\u2013883.","DOI":"10.1111\/cas.14756"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 2017; 18: 2780\u20132794.","DOI":"10.1016\/j.celrep.2017.02.033"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Feng E, Yang X, Yang J, Qu Q, Li X. LAMB1 promotes proliferation and metastasis in nasopharyngeal carcinoma and shapes the immune-suppressive tumor microenvironment. Brazilian Journal of Otorhinolaryngology. 2025; 91: 101551.","DOI":"10.1016\/j.bjorl.2024.101551"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Cai Z, Li J, Wu L, Hu X, Lin W, Peng B, et al. Laminin \u03b21 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma. International Journal of Biological Macromolecules. 2026; 336: 149150.","DOI":"10.1016\/j.ijbiomac.2025.149150"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Tantimetta P, Chaimeteveth N, Nounsuwan K, Urairat C, Yongpraderm D, Rattanaarchanai T, et al. TCGA and bioinformatics reveal the molecular network and prognostic implication of Laminin beta 1 in cholangiocarcinoma. Current Applied Science And Technology. 2025; 2025: e0267583.","DOI":"10.55003\/cast.2025.267583"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kerdkumthong K, Roytrakul S, Songsurin K, Pratummanee K, Runsaeng P, Obchoei S. Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma. Biomolecules. 2024; 14: 969.","DOI":"10.3390\/biom14080969"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Islam K, Thummarati P, Kaewkong P, Sripa B, Suthiphongchai T. Role of laminin and cognate receptors in cholangiocarcinoma cell migration. Cell Adhesion & Migration. 2021; 15: 152\u2013165.","DOI":"10.1080\/19336918.2021.1924422"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Sritananuwat P, Sueangoen N, Thummarati P, Islam K, Suthiphongchai T. Blocking ERK1\/2 signaling impairs TGF-\u03b21 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells. Cancer Cell International. 2017; 17: 85.","DOI":"10.1186\/s12935-017-0454-2"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Jing C, Li H, Du Y, Cao H, Liu S, Wang Z, et al. MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells. Molecular Medicine Reports. 2019; 19: 1092\u20131100.","DOI":"10.3892\/mmr.2018.9730"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Jamnongsong S, Kueanjinda P, Buraphat P, Sakornsakolpat P, Vaeteewoottacharn K, Okada S, et al. Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. iscience. 2022; 25: 105182.","DOI":"10.1016\/j.isci.2022.105182"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL52847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:22:49Z","timestamp":1790698969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL52847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02275-6"],"URL":"https:\/\/doi.org\/10.31083\/fbl52847","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"52847"}}